13FPulse
中
AB

ABCL ABCELLERA BIOLOGICS INC

2026Q2 · CUSIP 00288U106 · Sector: Healthcare & Biotech

Normal

Fund flows are within the usual range

Funds that own it
150
Institutions that reported holding it to the SEC
Net increase in holders
+15
Last quarter 135 → now 150
How unusual is that
Above average
Stronger buying than 78% of US stocks
What the filings say, in one paragraph

150 funds held ABCL at the end of 2026Q2, up 15 from the quarter before. Fund flows are within the usual range — nothing unusual. On the business itself, revenue over the last 12 months was $66M(YoY +101.3%), return on equity is -18.4%. ABCL has had 4 buying rushes in its history, and the price moved -44.4% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.

How many funds owned it, quarter by quarter

Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.

2021Q1: holders=84 2021Q2: holders=112 2021Q3: holders=115 2021Q4: holders=120 2022Q1: holders=128 2022Q2: holders=158 2022Q3: holders=187 2022Q4: holders=201 2023Q1: holders=181 2023Q2: holders=168 2023Q3: holders=137 2023Q4: holders=143 2024Q1: holders=153 2024Q2: holders=148 2024Q3: holders=137 2024Q4: holders=144 2025Q1: holders=127 2025Q2: holders=126 2025Q3: holders=141 2025Q4: holders=143 2026Q1: holders=135 2026Q2: holders=150 -31 -15.5 +0 +15.5 +31 75144212 21Q121Q322Q122Q323Q123Q324Q124Q325Q125Q326Q126Q2 Net change in holders (bars) Total funds holding (line)

What happened after each past buying rush 4 times in its history

Quarter of the rush How unusual then Price, next 3 months Price, next 6 months
2022Q3 Top 5% -34.0% -59.8%
2022Q2 Top 5% +11.4% -27.0%
2021Q2 Top 10% -2.3% -41.5%
2021Q1 Top 20% -48.2% -49.4%

These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.

Show all the numbers (large funds, value held, options…) ▾
Of them, large funds
72
Change in large funds
+3
Total value they hold
$909M
Funds buying for the first time
42
Funds that sold out entirely
27
Price change that quarter
+176.0%
Funds holding puts (bearish)
8
Funds holding calls (bullish)
7

These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.

8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.

Fundamentals

PE (TTM)
—
EPS (TTM)
$-0.54
EPS YoY
—
Revenue (TTM)
$0.1B
Revenue YoY
+101.3%
Net margin
-248.8%
ROE
-18.4%
Debt ratio
31.5%
FCF (TTM)
-$120M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS
2021-09-30: EPS -0.08 2021-12-31: EPS 0.20 2022-03-31: EPS 0.54 2022-06-30: EPS -0.02 2022-09-30: EPS 0.08 2022-12-31: EPS -0.10 2023-03-31: EPS -0.14 2023-06-30: EPS -0.11 2023-09-30: EPS -0.10 2023-12-31: EPS -0.16 2024-03-31: EPS -0.14 2024-06-30: EPS -0.13 2024-09-30: EPS -0.17 2024-12-31: EPS -0.11 2025-03-31: EPS -0.15 2025-06-30: EPS -0.12 2025-09-30: EPS -0.19 2025-12-31: EPS -0.03 2026-03-31: EPS -0.14 2026-06-30: EPS -0.18 0M 158M 317M $M -0.21 0.19 0.59 202020212022202320242025202606/26 Revenue EPS

Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time
16 19 21 20222023202420252026

P/E = close around day 47 after quarter-end ÷ TTM EPS then; this is a consistent valuation date, not the company’s actual filing date; loss quarters hidden

Quarterly free cash flow
-139M51M242M 2020202120222023202420252026
Latest quarter $-37M (2026-03-31)

FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden

As of 2026-06-30 · SEC filings (XBRL)

Email me the next update

2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.